메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Revolutionary Myopia Management Technology Expands Across Asia -- Kubota Glass Makes Global Debut at ASEAN International Optics Fair Bangkok 2025

TOKYO, Oct. 7, 2025 -- Kubota Pharmaceutical Holdings Co., Ltd. (TSE: 4596) today announced that its groundbreaking myopia management device, Kubota Glass, will make its international debut at ASEAN International Optics Fair Bangkok 2025, taking place in Bangkok, Thailand, from October 9-11, 2025. Addressing Asia's Myopia Crisis With half of the world's population projected to become myopic by 2050, childhood myopia progression has emerged as a critical public health challenge, particularly across Asia where prevalence rates are among the highest globally. Current treatm
- 김갑성 기자
- 2025-10-07 10:00
Chula's "Smart Salt" Wins Gold for Cutting Sodium Without Losing Flavor

BANGKOK, Oct. 7, 2025 -- "Smart Salt," an innovative low-sodium salt developed by Paul Patsapong Chomchey, a Ph.D. candidate at Chulalongkorn University and Executive MBA alumnus, has won a Gold Medal and Special Award at the 2025 Silicon Valley International Invention Festival. Using Nano Chitosan technology, Smart Salt cuts sodium by more than half while preserving full flavor, offering a breakthrough solution to the global health challenge of excessive salt consumption. Paul Patsapong Chomchey, a graduate of Chulalongkorn University's Executive MBA Program, Class
- 김갑성 기자
- 2025-10-07 09:00
UEG Week 2025: Microplastics found to change gut microbiome in first human-sample study

BERLIN, Oct. 7, 2025 -- New research presented today at UEG Week 2025 shows that microplastics – plastic particles smaller than 5mm commonly found in the environment – can alter the human gut microbiome, with some changes resembling patterns linked to depression and colorectal cancer. This study, conducted within the framework of microONE, a pioneering COMET Module programme project led by CBmed research center in collaboration with international partners, is among the first to directly examine how different types of microplastics interact with the human gut microbiome. As part of micr
- 김갑성 기자
- 2025-10-07 06:01
UEG 위크 2025: 최초의 인간 샘플 연구에서 미세플라스틱 노출에 따른 장내 미생물 구성 변화 확인

베를린, 2025년 10월 7일 -- 우리 주변 환경에서 흔히 발견되는 5mm 미만의 플라스틱 입자인 미세플라스틱이 인간의 장내 미생물(gut microbiome)을 변화시킬 수 있고, 일부 변화는 우울증 및 대장암에서 나타나는 변화 패턴과 유사한 것으로 UEG 위크 2025(UEG Week 2025)에서 6일 발표된 새로운 연구결과를 통해 확인됐다. 씨비메드(CBmed) 연구 센터가 국제 파트너들과 협력해 주도한 선구적인 코밋(COMET) 모듈 프로그램의 일환으로 진행된 마이크로원(microONE) 프로젝트에서 수행된 본 연구는 다양한 유형의 미세플라스틱이 인간 장내 미생물과 어떻게 상호작용하는지 직접 조사한 최초의 연구에 속한다. 인체 내에서 미세 및 나노 플라스틱 입자의 영향을 탐구하겠다는 마이크로원의 광범위한 사명의 일환으로 추진된 이번 연구는 미세플라스틱이 건강에 미칠 수 있는 잠재적 영향에 대한 중요한 새로운 통찰을 제공해주는 동시에 추가 연구의 필요성이 시급함을 확인시켜준다. 연구진은 건강한 자원자 5명의 대변 샘플을 이용해 체외(ex vivo) 장내 미생물 배양을 수행했다. 이어 배양체를 폴리스티렌, 폴리프로필렌,
- 김갑성 기자
- 2025-10-07 06:01
MPF Powers a Mission-Critical Rebuild of Bridge2Practise: From Legacy Chaos to a Future-Ready Clinical Education Platform

SYDNEY, Oct. 7, 2025 -- Miroma Project Factory (MPF) has partnered with the University of Sydney to deliver a high-stakes, deeply technical modernisation of Bridge2Practise—a clinical skills training platform used by medical students and educators to simulate and assess procedural learning. Behind the scenes, Bridge2Practise was running on a five-year-old version of MeteorJS, linked to a deprecated database platform, with manual deployments, missing infrastructure documentation, and broken user flows. A growing backlog of bugs, performance issues, and unfulfilled feature reques
- 김갑성 기자
- 2025-10-07 05:07
NCCN Guidelines Navigator for Breast Cancer Genetic Testing and Treatment Debuts During Breast Cancer Awareness Month

[ 메디채널 김갑성 기자 ] The National Comprehensive Cancer Network expands interactive library of evidence-based, expert consensus-driven cancer care guidance to now cover treatment for more than a dozen cancer types, along with hereditary risk assessment, featuring seamless integration with additional resources. PLYMOUTH MEETING, Pa., Oct. 6, 2025 -- Today, the National Comprehensive Cancer Network® (NCCN®)—a nonprofit responsible for globally utilized guidelines for cancer care—is sharing new NCCN Guidelines Navigator™ resources for breast cancer treatment as well as genetic/familia
- 김갑성 기자
- 2025-10-06 21:04
Halia Therapeutics Strengthens Global Genomics Leadership with Appointment of Paul Jones as Chief Strategy Officer & GM, International Markets

New CSO & GM role underscores Halia's commitment to resilience-based therapeutic development and advances collaboration with the Department of Health – Abu Dhabi LEHI, Utah, Oct. 6, 2025 -- Halia Therapeutics (The Genetic Resilience Company), a clinical-stage biopharmaceutical company developing first-in-class anti-inflammatory therapies, today announced the appointment of Paul Jones as Chief Strategy Officer & GM, International Markets. In this newly created role, Jones will focus on accelerating GENMOR-AI, the company's proprietary platform for identifying genetic mo
- 김갑성 기자
- 2025-10-06 20:15
Yesoul T3S Plus Auto-Incline Treadmill with Free Screen Mirroring: Affordable Innovation for Your Marathon Training at Home

HONG KONG, Oct. 6, 2025 -- For many people, finding time to exercise feels impossible. After a long day at work, commuting home, preparing meals, and taking care of family, the idea of heading to a crowded gym is exhausting. Even when you carve out time at home, traditional treadmills can be frustrating—bulky machines take up half your living room, noisy motors disrupt the household, and most require expensive subscriptions just to access the full experience. The result? Your motivation fades, workouts get skipped, and your fitness goals feel farther away. Enter the Yesoul T3S Plus Au
- 노기식 기자
- 2025-10-06 19:00
Olympus and W. L. Gore & Associates Enter into International Distribution Agreement to Expand the Olympus EndoTherapy Portfolio

CENTER VALLEY, Pa., and HAMBURG, Germany, Oct. 6, 2025 -- Olympus Corporation, a global MedTech company committed to making people's lives healthier, safer and more fulfilling, has entered into an international distribution agreement with the medical products business of U.S.-based W. L. Gore & Associates, Inc. (hereinafter Gore), a global materials science company that develops innovative products across diverse industries. The agreement allows Olympus to become the exclusive international distributor and have distribution rights of the GORE® VIABIL® Biliar
- 김갑성 기자
- 2025-10-06 15:00
FDA Lifts Clinical Hold on NUZ-001

Highlights: U.S. FDA lifts the Clinical Hold on NUZ‑001, Neurizon®'s lead investigational therapy for ALS Clears the way for entry into the HEALEY ALS Platform Trial expected to commence in Q4 CY2025 IND supported by robust preclinical safety data and comprehensive manufacturing and quality information from the previously signed Elanco licensing agreement Expedites NUZ-001 as a platform molecule with pipeline expansion potential Positions Neurizon for accelerated regulatory pathways and future partnering opportunities MELBOURNE, Australia, Oct. 6, 2025
- 김갑성 기자
- 2025-10-06 14:06

이전

31 32 33 34 35 36 37 38 39 40

많이 본 기사

최근기사

2025-11-04_TUE

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 05일 01시 20분